Altering microbial populations & modifying microbiota

Abstract

The invention relates to methods, uses, systems, arrays, engineered nucleotide sequences and vectors for inhibiting bacterial population growth or for altering the relative ratio of sub-populations of first and second bacteria in a mixed population of bacteria. The invention is particularly useful, for example, for treatment of microbes such as for environmental, medical, food and beverage use. The invention relates inter alia to methods of controlling microbiologically influenced corrosion (MIC) or biofouling of a substrate or fluid in an industrial or domestic system.

1 - 24 . (canceled) 
     
     
         25 : A method for modifying a target sequence comprised by a bacterial or archaeal host cell, the method comprising:
 (a) contacting the host cell with an engineered nucleic acid for producing a host modifying crRNA (HM-crRNA), and   (b) producing the HM-crRNA in the host cell;   wherein   (i) the HM-crRNA is operable with a Type II Cas and a tracrRNA in the host cell, wherein the engineered nucleic acid, the tracrRNA and the Type II Cas are comprised by a Type II HM-CRISPR/Cas system in the host cell;   (ii) the HM-crRNA comprises a nucleotide sequence that is capable of hybridizing to the target sequence in the host cell to guide the Type II Cas to modify the target sequence in the host cell; and   (iii) the tracrRNA is an endogenous tracrRNA of the host cell;   wherein the target sequence is modified by the Type II HM-CRISPR/Cas system.   
     
     
         26 : The method of  claim 25 , wherein the host cell is killed or growth of the host cell is inhibited. 
     
     
         27 : The method of  claim 25 , wherein the Type II Cas is a Cas9. 
     
     
         28 . (canceled) 
     
     
         29 : The method of  claim 27 , wherein the Type II Cas is a  Streptococcus  Cas9. 
     
     
         30 : The method of  claim 25 , wherein the engineered nucleic acid for producing the HM-crRNA is present in a phage, phagemid or plasmid. 
     
     
         31 : The method of  claim 25 , wherein the target sequence is a host target sequence. 
     
     
         32 : The method of  claim 29 , wherein the Type II Cas is a spCas9 or saCas9. 
     
     
         33 : The method of  claim 25 , wherein the method is for medical, dental or ophthalmic use. 
     
     
         34 : The method of  claim 25 , wherein the host cell is comprised by a plant. 
     
     
         35 : The method of  claim 34 , wherein the plant is a crop. 
     
     
         36 : The method of  claim 25 , wherein the host cell is comprised by an animal. 
     
     
         37 : The method of  claim 36 , wherein the animal is a human. 
     
     
         38 : The method of  claim 25 , wherein the host cell is a cell type found in human microbiota. 
     
     
         39 : The method of  claim 25 , wherein the method is for medical, dental or ophthalmic use, and wherein the host cell is comprised by an animal or a human. 
     
     
         40 : The method of  claim 25 , wherein the method is for environmental or agricultural use, and wherein the host cell is comprised by a plant. 
     
     
         41 : The method of  claim 25 , wherein the host cell is a type of cell that infects an organism selected from a plant or an animal. 
     
     
         42 : The method of  claim 25 , wherein the host cell is in a mixed population of bacteria, the mixed population comprises a first bacterial sub-population and a second bacterial sub-population, wherein the first bacterial sub-population comprises a first bacterial species and the second bacterial sub-population comprises the host cell, wherein the host cell is of a second bacterial species, wherein the second bacterial species is a different species than the first bacterial species.